Abstract 5690
Background
Diabetes mellitus (DM) is a risk factor for pancreatic NETs, but its prognostic role in stage IV NETs is less defined. We evaluated the impact of diabetes on PFS in patients with advanced, non-functioning GEP-NETs.
Methods
Post hoc analysis of data from the phase III double-blind, placebo-controlled CLARINET study (NCT00353496) to investigate association between DM (any of: medical history of type 1 or 2; use of antihyperglycemic medication; HbA1c ≥6.5%, fasting plasma glucose ≥7mmol/L; non-fasting plasma glucose ≥11.11mmol/L [at baseline or during study]) and PFS (Kaplan-Meier). Multivariate Cox analysis including treatment (LAN vs PBO), DM at baseline, previous therapy and progression at baseline was used to test interaction between DM and LAN efficacy.
Results
The overall population (total, n = 204; LAN, n = 101; PBO, n = 103) had well-differentiated (Ki-67 <10%) foregut (45%), midgut (36%), or hindgut (7%) and unknown (13%) NET. 79 patients had DM, 125 did not (N-DM); 24 received metformin in combination with LAN (n = 14) or PBO (n = 10). Median PFS (mPFS) was 96.0 months (mo) [95% CI: 70.4; not reached (NR)] for DM vs 98.0 mo [72.1;NR] for N-DM (HR 1.20 [0.79;1.82], p = 0.38). For DM, mPFS with LAN (n = 42) was NR [95.9;NR] vs 60.0 mo [48.0;74.4] with PBO (n = 37) (HR 0.27, [0.13-0.57], p = 0.0002). For N-DM, mPFS with LAN (n = 59) was NR [96.0;NR] vs 72.1 mo [52.0;NA] with PBO (n = 66) (HR 0.64 [0.35-1.15], p = 0.04). In multivariate analysis, DM at baseline was not significantly associated with PFS (HR 1.64 [0.95;2.84], p = 0.08). Significant impact of LAN on PFS was confirmed (HR 0.53 [0.31;0.89], p = 0.02), without significant interaction between LAN efficacy and DM (p = 0.62).
Conclusions
DM did not emerge as a negative prognostic factor in advanced stage IV NETs. Efficacy of LAN in DM and N-DM was confirmed. Although LAN–DM interaction was not significant, LAN efficacy seemed particularly favorable in DM compared to N-DM patients, in terms of HR. These findings, along with a potential favorable association with hypoglycemic drugs such as metformin, should be evaluated and validated in prospective biomarker studies.
Clinical trial identification
Post hoc analisys of phase III double-blind, placebo-controlled CLARINET study (NCT00353496).
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Editorial Acknowledgement
Editorial assistance for the preparation of this abstract was provided by Emma Leah, Global Publications Manager, Rare Diseases, Ipsen.
Disclosure
S. Pusceddu: Honoraria, advisory boards: Novartis; Research funding, honoraria, advisory boards, consulting role, grants: Ipsen; Advisory boards: Italfarmaco; Research funding, advisory boards, grants: Pfizer; Advisory boards: Advanced Accelerate Application (AAA). R. Buzzoni: Research funding, advisory boards: Ipsen. F.G.M. de Braud: Research funding, honoraria, advisory boards, consulting role, grants: Ipsen. N. Prinzi: Honoraria: Ipsen. X-M. Truong-Thanh: Employment: Ipsen. V. Mazzaferro: Honoraria: Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract